Organization | Synthetic Biologics

Synthetic Biologics Report issue

For profit Phase 1 Phase 2

Founded: Rockville MD United States (2001)

Organization Overview

First Clinical Trial

2015

NCT02419001

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Synthetic Biologics Inc.

Active Ingredients

Drugs in Phase 2 Trials (5)

bay2433334 (1 trial)

ceftriaxone (rocephin) (2 trials)

esomeprazole (nexium) (1 trial)

syn-004 (3 trials)

syn-010 (3 trials)

Drugs in Phase 1 Trials (6)

Key: Synthetic Biologics (1) Acquired (5)

bovine intestinal alkaline phosphatase (2 trials)

durvalumab (imfinzi) (1 trial)

gemcitabine (gemzar) (2 trials)

mesothelin car t cells (1 trial)

paclitaxel (taxol) (2 trials)

vcn-01 (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Clostridium Infections (Phase 2)

Constipation (Phase 2)

Infections (Phase 2)

Irritable Bowel Syndrome (Phase 2)

Syndrome (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 13
# of Trial APIs: 11